EUVIMEDEUVIMED entdecken
Open Access

A value-based budget impact model for dronedarone compared with other rhythm control strategies

Jennifer Ken-Opurum, Sesha Ss Srinivas, Pratyusha Vadagam, Lang Faith, Seojin Park, Scott Charland, Andrew Revel, Ronald Preblick

Journal of Comparative Effectiveness Research · 2023

DOI: 10.57264/cer-2022-0196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2023. Verfasst von Jennifer Ken-Opurum und 7 weiteren Autor:innen. Beteiligte Einrichtung: Axtria Inc., Decision Science, Health Economics and Outcomes Research / Real-World Evidence, Berkley Heights, NJ 07922, USA. Hauptthemen laut MEDLINE: Amiodarone, Atrial Fibrillation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The budgetary consequences of increasing dronedarone utilization for treatment of atrial fibrillation were evaluated from a US payer perspective. Materials & methods: A budget impact model over a 5-year time horizon was developed, including drug-related costs and risks for long-term clinical outcomes (LTCOs). Treatments included antiarrhythmic drugs (AADs; dronedarone, amiodarone, sotalol, propafenone, dofetilide, flecainide), rate control medications, and ablation. Direct comparisons and temporal and non-temporal combination scenarios investigating treatment order were analyzed as costs per patient per month (PPPM).

Results

By projected year 5, costs PPPM for dronedarone versus other AADs decreased by $37.69 due to fewer LTCOs, treatment with dronedarone versus ablation or rate control medications + ablation resulted in cost savings ($359.94 and $370.54, respectively), and AADs placed before ablation decreased PPPM costs by $242 compared with ablation before AADs.

Conclusion

Increased dronedarone utilization demonstrated incremental cost reductions over time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmiodaroneAtrial FibrillationHumansDronedaroneAnti-Arrhythmia AgentsSotalol

Stichwörter der Autor:innen

cardiology/cardiovascularcomparative effectiveness researchhealth economics

Substanzen

DronedaroneAnti-Arrhythmia AgentsAmiodaroneSotalol

Autor:innen und Institutionen

  • Axtria Inc., Decision Science, Health Economics and Outcomes Research / Real-World Evidence, Berkley Heights, NJ 07922, USA.
  • Sanofi US, US General Medicines, Bridgewater, NJ 08807, USA.

Förderung

  • Sanofi

Zitieren

APA

Ken-Opurum, J., Srinivas, S. S., Vadagam, P., Faith, L., Park, S., Charland, S., Revel, A., & Preblick, R. (2023). A value-based budget impact model for dronedarone compared with other rhythm control strategies. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2022-0196

Vancouver

Ken-Opurum J, Srinivas SS, Vadagam P, Faith L, Park S, Charland S, et al. A value-based budget impact model for dronedarone compared with other rhythm control strategies. Journal of Comparative Effectiveness Research. 2023. doi:10.57264/cer-2022-0196

BibTeX
@article{KenOpurum2023,
  author = {Ken-Opurum, Jennifer and Srinivas, Sesha Ss and Vadagam, Pratyusha and Faith, Lang and Park, Seojin and Charland, Scott and Revel, Andrew and Preblick, Ronald},
  title = {A value-based budget impact model for dronedarone compared with other rhythm control strategies},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2023},
  doi = {10.57264/cer-2022-0196}
}
Kostenlos starten →